Insulin aspart (NovoRapid/Novolog) and insulin lispro (Humalog) are the two most widely used rapid-acting insulin analogues. Despite sharing the same pharmacological class, they differ subtly in pharmacokinetic profiles, formulation options, and clinical positioning. Understanding these distinctions informs optimal postprandial glucose management.
Molecular Modifications
Section titled “Molecular Modifications”Insulin Lispro
Section titled “Insulin Lispro”Lispro is produced by reversing the amino acid order at positions B28 (Pro) and B29 (Lys) of human insulin. This inversion disrupts the hexameric self-association that stabilizes native insulin, producing faster dissociation into monomers after subcutaneous injection.
- Sequence change: B28-Pro, B29-Lys → B28-Lys, B29-Pro
- Mechanism of fast action: Reduced dimerization and hexamer formation
- Concentration: 100 units/mL (U-100) or 200 units/mL (U-200)
Insulin Aspart
Section titled “Insulin Aspart”Aspart substitutes aspartic acid for proline at position B28, similarly disrupting hexameric stability. The charged aspartate residue creates electrostatic repulsion between monomers.
- Sequence change: B28-Pro → B28-Asp
- Mechanism of fast action: Reduced self-association via charge repulsion
- Concentration: 100 units/mL (U-100), 200 units/mL (U-200), or 50 units/mL in Fiasp
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | Insulin Lispro | Insulin Aspart |
|---|---|---|
| Onset of action | 5–15 minutes | 5–15 minutes |
| Peak concentration | 30–90 minutes | 30–90 minutes |
| Time to maximal effect | 1–3 hours | 1–3 hours |
| Duration of action | 3–5 hours | 3–5 hours |
| Bioavailability | ~55–65% | ~55–65% |
The pharmacokinetic profiles are remarkably similar for standard formulations. Both achieve:
- Rapid onset (5–15 minutes)
- Peak effect at 1–3 hours
- Complete activity within 4–5 hours
Minor Differentiators
Section titled “Minor Differentiators”Onset speed: Some studies suggest insulin lispro may have a marginally faster onset (5–10 minutes) compared to aspart (10–15 minutes), though this difference is clinically negligible in most patients.
Duration: Insulin aspart may have a slightly shorter tail of activity (~3–4 hours) compared to lispro (~4–5 hours), which could influence late postprandial glucose excursions.
Variability: Both analogues show similar intra-individual variability (~20–30% CV), substantially lower than regular human insulin (~35–45% CV).
Formulation Variants
Section titled “Formulation Variants”Ultra-Rapid Formulations
Section titled “Ultra-Rapid Formulations”| Formulation | Onset | Peak | Key Feature |
|---|---|---|---|
| Lispro (Humalog) | 5–15 min | 1–3 hr | Standard |
| Aspart (NovoRapid) | 5–15 min | 1–3 hr | Standard |
| Fiasp (faster aspart) | 2.5× faster | ~50% earlier | Added niacinamide |
| Lispro (Lyumjev) | 2× faster | Earlier | Added treprostinil + citrate |
| Aspart (NovoRapid) | Standard | Standard | — |
Fiasp (faster-acting insulin aspart) contains niacinamide (vitamin B₃) as a permeation enhancer, accelerating initial absorption. Fiasp achieves measurable insulin levels ~5 minutes after injection vs. ~10–15 minutes for standard aspart, with ~50% higher insulin exposure in the first 30 minutes.
Lyumjev (ultra-rapid lispro) contains treprostinil (a prostacyclin analogue) and citrate buffer to accelerate local vasodilation and tissue permeation. Lyumjev achieves earlier onset than standard lispro, with ~40% higher insulin exposure in the first 30 minutes.
Clinical Implications
Section titled “Clinical Implications”Postprandial Glucose Control
Section titled “Postprandial Glucose Control”Both agents effectively manage postprandial glucose excursions when dosed at meal start:
- Pre-meal dosing: Both achieve peak effect within 1–2 hours, aligning with carbohydrate absorption.
- Post-meal dosing: Both can be administered within 15–20 minutes after meal start with similar efficacy.
- High-fat meals: Both may require dose splitting or extended bolus (dual wave) to address delayed fat/protein absorption.
Insulin Pump Use
Section titled “Insulin Pump Use”| Property | Lispro | Aspart |
|---|---|---|
| Stability in pump | 24–48 hours (reservoir) | 24–48 hours (reservoir) |
| Occlusion risk | Low | Low |
| Warm-up time | Short | Short |
| FDA-approved for pump | Yes | Yes |
| Cartridge life | 24–72 hours | 24–72 hours |
Both analogues perform comparably in continuous subcutaneous insulin infusion (CSII) systems, with low occlusion rates and stable pharmacokinetics at body temperature.
Hybrid Closed-Loop Systems
Section titled “Hybrid Closed-Loop Systems”In automated insulin delivery (AID) systems:
- Lispro: Used in Medtronic 780G, Omnipod 5, and Tandem Control-IQ algorithms.
- Aspart: Used in Omnipod 5 and some European AID systems.
- Fiasp/Lyumjev: Preferred in some advanced algorithms due to faster onset reducing post-meal spikes.
Adverse Effects
Section titled “Adverse Effects”| Effect | Lispro | Aspart |
|---|---|---|
| Hypoglycemia | 10–15% | 10–15% |
| Weight gain | 1–3 kg over 6 months | 1–3 kg over 6 months |
| Injection site reactions | 1–5% | 1–5% |
| Lipodystrophy | Rare (with rotation) | Rare (with rotation) |
| Allergic reactions | Very rare | Very rare |
Both agents have comparable safety profiles. Hypoglycemia risk is influenced more by dose accuracy and basal insulin adequacy than by the choice between lispro and aspart.
Cost and Access
Section titled “Cost and Access”| Factor | Lispro (Humalog) | Aspart (NovoRapid) |
|---|---|---|
| List price (10 mL vial) | ~$300–350 | ~$300–350 |
| Biosimilar available | Yes (Admelog, others) | Yes (Fiasp, others) |
| 340B pricing | Available | Available |
| Insurance coverage | Broad | Broad |
The market has become increasingly competitive with biosimilar entry, reducing the cost differential between the two agents.
Summary
Section titled “Summary”Insulin aspart and insulin lispro are pharmacologically equivalent rapid-acting analogues with virtually identical onset, peak, and duration profiles. The choice between them is driven primarily by formulation preference (standard vs. ultra-rapid), pump compatibility, algorithm preference in AID systems, and cost/access considerations. Ultra-rapid formulations (Fiasp, Lyumjev) offer modestly faster onset for patients requiring aggressive postprandial coverage. Neither agent demonstrates clear superiority in clinical outcomes, and switching between them is generally seamless with no dose adjustment required.